Trials
Search / Trial NCT05653388

Metastatic Leiomyosarcoma Biomarker Protocol

Launched by UNIVERSITY OF MICHIGAN ROGEL CANCER CENTER · Dec 7, 2022

Trial Information

Current as of January 22, 2025

Recruiting

Keywords

Ct Dna Biomarker Radiomics

ClinConnect Summary

This clinical trial is focused on studying a type of cancer called metastatic leiomyosarcoma (LMS), which is a serious condition where the cancer has spread from its original site to other parts of the body. The researchers want to find out if a specific type of DNA found in the blood, called circulating tumor DNA (ctDNA), can help predict how well patients respond to chemotherapy. By analyzing blood samples and tumor tissues from patients undergoing treatment, the study aims to identify early signs that could indicate whether the chemotherapy is working, which could significantly help in planning future treatments.

To be eligible for this trial, patients must have advanced leiomyosarcoma that cannot be surgically removed and must be starting their first round of chemotherapy using specific drugs. There are no age restrictions, but participants must also have certain tumor characteristics. Those who join the study can expect to provide blood samples, tumor tissue, and complete a questionnaire about their views on genetics and genetic testing. This research is actively recruiting participants, and it's an important step toward improving treatment strategies for this challenging cancer.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients with unresectable or metastatic leiomyosarcoma (LMS). There is no age requirement
  • Receiving first-line chemotherapy with doxorubicin or gemcitabine/docetaxel
  • Target lesions per RECIST 1.1
  • Optional archival tumor tissue including 1 H\&E-stained slide and unstained tumor tissue \[either tissue block containing tumor, or minimum of 4 unstained slides (preferably 8 unstained slides)-fresh frozen sample may also be used in lieu of FFPE sample\] available for study research

Trial Officials

Scott Schuetze

Principal Investigator

University of Michigan Rogel Cancer Center

About University Of Michigan Rogel Cancer Center

The University of Michigan Rogel Cancer Center is a leading academic research institution dedicated to advancing cancer treatment and prevention through innovative clinical trials. As a National Cancer Institute-designated Comprehensive Cancer Center, it combines cutting-edge research, state-of-the-art facilities, and a multidisciplinary team of experts to deliver personalized care and foster groundbreaking discoveries. The center's commitment to improving patient outcomes is reflected in its robust portfolio of clinical trials, which explore novel therapies and enhance understanding of cancer biology. Through collaboration with patients, researchers, and healthcare professionals, the Rogel Cancer Center aims to translate scientific insights into transformative therapies, ultimately contributing to the global fight against cancer.

Locations

Rochester, Minnesota, United States

Columbus, Ohio, United States

New York, New York, United States

Nashville, Tennessee, United States

Ann Arbor, Michigan, United States

Rochester, Minnesota, United States

Houston, Texas, United States

Melbourne, Victoria, Australia

Camperdown, New South Wales, Australia

Boston, Massachusetts, United States

Sydney, Unsw, Australia

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials